Tag

Khiron's Zerenia is to provide "Integrative Health Services and Pharmacotherapeutic Treatment with Medical Cannabis" to Capital Salud patients.

The Khiron sponsored study found 9 out of 10 patients reported some degree of improvement of their chronic pain.

The 4,000 square foot facility features 11 patient rooms and according to Khiron, can handle 40,000 patient consultations per year.

Medical marijuana derivatives are included in the expansive resolution for the first time, though some private insurers had already included cannabis trreatments.

Khiron has a sales presence in Colombia, Peru, Germany, UK, and Brazil and is positioned to commence sales in Mexico.

Q3 2021 revenue increased 83% YoY to $3.5 million compared to the previous year. Continued strong gross margins for medical cannabis segment at 89%

The medical cannabis treatment study shows positive results in more than 80% of participants with only minor side-effects.

Year to date medical cannabis prescriptions have exceeded 35,000 units, 600% more than the entire 2020 fiscal year. Khiron will expand its flagship clinic brand, Zerenia to the UK, with the first Zerenia opening in London in Q4 2021.

Khiron says the report adheres to global reporting initiative (GRI) standards and reflects the alignment of Khiron's goals with the United Nations Sustainable Development Goals.

Khiron plans to launch its Zerenia clinics across Mexico in 2021, building on the success of its vertically integrated model in Colombia and Peru, & leveraging its education partnership with Tecnologico de Monterrey.